Health Care·Biotechnology·$2.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.60 | N/A | +14.23% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.60 | N/A | +14.23% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious outlook, emphasizing the importance of their clinical programs. They did not offer specific guidance for future revenue.
Management did not provide specific revenue guidance for the upcoming quarters.
The company remains focused on its ongoing clinical trials.
Sarepta Therapeutics reported a wider-than-expected loss per share, which was a positive surprise compared to analyst expectations. However, the lack of revenue figures and guidance contributed to a slight decline in the stock price by 0.4%. Investors may be concerned about the company's future revenue potential given the absence of specific guidance and the focus on clinical trials.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CANADIAN NATL RY CO
Apr 24, 2017